These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 33546172)

  • 1. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements.
    Jin KT; Du WL; Liu YY; Lan HR; Si JX; Mou XZ
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of oncolytic virotherapy: from genetic modification to combination therapy.
    Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
    Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
    Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW
    J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy.
    Zhang Y; Li Y; Chen K; Qian L; Wang P
    Cancer Cell Int; 2021 May; 21(1):262. PubMed ID: 33985527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment.
    Wang L; Chard Dunmall LS; Cheng Z; Wang Y
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arming oncolytic viruses to leverage antitumor immunity.
    de Gruijl TD; Janssen AB; van Beusechem VW
    Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
    Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
    Front Immunol; 2021; 12():721830. PubMed ID: 34675919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
    Muscolini M; Tassone E; Hiscott J
    Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
    Sadri M; Najafi A; Rahimi A; Behranvand N; Hossein Kazemi M; Khorramdelazad H; Falak R
    Int Immunopharmacol; 2023 Sep; 122():110470. PubMed ID: 37433246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.
    Ban W; Guan J; Huang H; He Z; Sun M; Liu F; Sun J
    Nano Res; 2022; 15(5):4137-4153. PubMed ID: 35194488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells.
    Soroush A; Shahhosseini R; Ghavamikia N; Hjazi A; Roudaki S; KhalatbariLimaki M; Mirbolouk M; Pakmehr S; Karimi P
    Cell Biochem Funct; 2024 Jun; 42(4):e4055. PubMed ID: 38856033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on immunotherapy via oncolytic viruses.
    Reale A; Vitiello A; Conciatori V; Parolin C; Calistri A; Palù G
    Infect Agent Cancer; 2019; 14():5. PubMed ID: 30792754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
    Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
    Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
    Hofman L; Lawler SE; Lamfers MLM
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.
    Chen L; Zuo M; Zhou Q; Wang Y
    Front Immunol; 2023; 14():1308890. PubMed ID: 38169820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy.
    Mamola JA; Chen CY; Currier MA; Cassady K; Lee DA; Cripe TP
    Mol Ther Oncolytics; 2023 Jun; 29():118-124. PubMed ID: 37250971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy.
    Wang S; Wei J
    Int J Cancer; 2022 Nov; 151(10):1654-1662. PubMed ID: 35633046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and application of oncolytic viruses for cancer immunotherapy.
    Ylösmäki E; Cerullo V
    Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virotherapy against the tumor microenvironment and its potential in pancreatic cancer.
    Zhang Y; Li Y; Chen K; Qian L; Wang P
    J Cancer Res Ther; 2022 Sep; 18(5):1247-1255. PubMed ID: 36204869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.